Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer
2024-518486-10-00Phase 2Authorised
- Sponsor
- SOLTI
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sasanlimab and sacituzumab govitecan in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC), sponsored by SOLTI. Primary endpoint: Complete response rate at 3 months. Planned start Oct 2024; status: authorised.
02
Drugs
sasanlimabsacituzumab govitecan
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-518486-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518486-10-00.